Long-Term Outcome After Histopathological Complete Response with and Without Nodal Metastases Following Multimodal Treatment of Esophageal Cancer.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
11 Apr 2022
11 Apr 2022
Historique:
received:
16
11
2021
accepted:
11
02
2022
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
12
4
2022
Statut:
aheadofprint
Résumé
This study analyzed the long-term survival after pathological complete response (pCR) with and without nodal metastases and associated recurrence following multimodal treatment of esophageal cancer. The recurrence pattern after pCR is of importance for different postoperative surveillance strategies. A cohort of 890 patients with esophageal cancer received neoadjuvant therapy followed by transthoracic esophagectomy. Only patients with pCR of the primary tumor with and without nodal metastasis were analyzed. A clinicopathological database was set up and completed with long-term follow up information on recurrent disease. The specimen of 201 patients (23%) demonstrated pCR, 84% without (ypT0N0) and 16% with residual nodal disease (ypT0N+). For ypT0N0 patients, the 5-year overall survival was significantly higher than for patients with metastatic nodes (77% vs. 24%) (p < 0.0001). Sixty-eight percent of patients had no evidence of tumor recurrence, whereas 32% had proven relapse. For patients with and without tumor recurrence, 5-year survival rates were 14% and 93%, respectively (p < 0.0001). For patients with recurrent disease, median survival time was 27 for locoregional, 44 for distant, and 24 months for combined recurrence (p = 0.302). In the multivariable Cox-regression analysis, node-positive disease predicted both locoregional and metastatic recurrence. Pathological CR offers long-term survival in patients without nodal metastases but outcome significantly deteriorates with the presence of nodal metastases. Follow-up recommendations may therefore be adopted in patients with pCR. Furthermore, "watch-and-wait" surveillance strategies with suspected clinical complete response have to be considered with caution.
Sections du résumé
BACKGROUND
BACKGROUND
This study analyzed the long-term survival after pathological complete response (pCR) with and without nodal metastases and associated recurrence following multimodal treatment of esophageal cancer. The recurrence pattern after pCR is of importance for different postoperative surveillance strategies.
METHODS
METHODS
A cohort of 890 patients with esophageal cancer received neoadjuvant therapy followed by transthoracic esophagectomy. Only patients with pCR of the primary tumor with and without nodal metastasis were analyzed. A clinicopathological database was set up and completed with long-term follow up information on recurrent disease.
RESULTS
RESULTS
The specimen of 201 patients (23%) demonstrated pCR, 84% without (ypT0N0) and 16% with residual nodal disease (ypT0N+). For ypT0N0 patients, the 5-year overall survival was significantly higher than for patients with metastatic nodes (77% vs. 24%) (p < 0.0001). Sixty-eight percent of patients had no evidence of tumor recurrence, whereas 32% had proven relapse. For patients with and without tumor recurrence, 5-year survival rates were 14% and 93%, respectively (p < 0.0001). For patients with recurrent disease, median survival time was 27 for locoregional, 44 for distant, and 24 months for combined recurrence (p = 0.302). In the multivariable Cox-regression analysis, node-positive disease predicted both locoregional and metastatic recurrence.
CONCLUSIONS
CONCLUSIONS
Pathological CR offers long-term survival in patients without nodal metastases but outcome significantly deteriorates with the presence of nodal metastases. Follow-up recommendations may therefore be adopted in patients with pCR. Furthermore, "watch-and-wait" surveillance strategies with suspected clinical complete response have to be considered with caution.
Identifiants
pubmed: 35403919
doi: 10.1245/s10434-022-11700-3
pii: 10.1245/s10434-022-11700-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022. Society of Surgical Oncology.
Références
Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50–7.
doi: 10.1093/annonc/mdw329
Porschen R, Fischbach W, Gockel I, et al. S3-Leitlinie – diagnostik und therapie der plattenepithelkarzinome und adenokarzinome des ösophagus. Z Gastroenterol. 2019;57:336–418.
doi: 10.1055/a-0833-5712
Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:855–83.
doi: 10.6004/jnccn.2019.0033
Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. 2013;31:CD008107.
Shapiro J, van Lanschot JJB, Hulshof M, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.
doi: 10.1016/S1470-2045(15)00040-6
Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17:1697–708.
doi: 10.1016/S1470-2045(16)30531-9
Straatman J, van der Wielen N, Cuesta MA, et al. Minimally invasive versus open esophageal resection: three-year follow-up of the previously reported randomized controlled trial: the TIME Trial. Ann Surg. 2017;266:232–6.
doi: 10.1097/SLA.0000000000002171
Low DE, Kuppusamy MK, Alderson D, et al. Benchmarking complications associated with esophagectomy. Ann Surg. 2019;269:291–8.
doi: 10.1097/SLA.0000000000002611
Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.
doi: 10.1016/S1470-2045(11)70142-5
Sudo K, Taketa T, Correa AM, et al. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013;31:4306–10.
doi: 10.1200/JCO.2013.51.7250
Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32:385–91.
doi: 10.1200/JCO.2013.51.2186
Robb WB, Messager M, Dahan L, et al. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone. Br J Surg. 2016;103:117–25.
doi: 10.1002/bjs.9959
Lee PC, Mirza FM, Port JL, et al. Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma. J Thorac Cardiovasc Surg. 2011;141:1196–206.
doi: 10.1016/j.jtcvs.2011.01.053
Peyre CG, Hagen JA, DeMeester SR, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549–56.
doi: 10.1097/SLA.0b013e318188c474
Visser E, van Rossum PSN, Ruurda JP, et al. Impact of lymph node yield on overall survival in patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy for cancer: a population-based cohort study in the Netherlands. Ann Surg. 2017;266:863–9.
doi: 10.1097/SLA.0000000000002389
Hölscher AH, Drebber U, Schmidt H, et al. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma. Ann Surg. 2014;260:779–84.
doi: 10.1097/SLA.0000000000000964
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.
doi: 10.1056/NEJMoa1112088
Vallböhmer D, Hölscher AH, DeMeester S, et al. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010;252:744–9.
doi: 10.1097/SLA.0b013e3181fb8dde
Xi M, Hallemeier CL, Merrell KW, et al. Recurrence risk stratification after preoperative chemoradiation of esophageal adenocarcinoma. Ann Surg. 2018;268:289–95.
doi: 10.1097/SLA.0000000000002352
Noordman BJ, Wijnhoven BPL, Lagarde SM, et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer. 2018;18:142.
doi: 10.1186/s12885-018-4034-1
XXXX
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma – English carcinoma - 2nd English edition. Gastric Cancer. 1998;1:10–24.
doi: 10.1007/PL00011681
Japan ES. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1–36.
doi: 10.1007/s10388-016-0551-7
Schröder W, Hölscher AH, Bludau M, et al. Ivor-Lewis esophagectomy with and without laparoscopic conditioning of the gastric conduit. World J Surg. 2010;34:738–43.
doi: 10.1007/s00268-010-0403-x
Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380:152–62.
doi: 10.1056/NEJMoa1805101
Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684–92.
doi: 10.1097/01.sla.0000186170.38348.7b
Brierley JD. TNM classification of malignant tumours. 8th edn. New Jersey: Wiley-Blackwell; 2017.
Meguid RA, Hooker CM, Taylor JT, et al. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg. 2009;138:1309–17.
doi: 10.1016/j.jtcvs.2009.07.069
Collée GE, van der Wilk BJ, van Lanschot JJB, et al. Interventions that facilitate shared decision-making in cancers with active surveillance as treatment option: a systematic review of literature. Curr Oncol Rep. 2020;22:101.
doi: 10.1007/s11912-020-00962-3
Eyck BM, Onstenk BD, Noordman BJ, et al. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Ann Surg. 2020;271:245–56.
doi: 10.1097/SLA.0000000000003397
Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol. 2018;19:965–74.
doi: 10.1016/S1470-2045(18)30201-8
van der Wilk BJ, Eyck BM, Doukas M, et al. Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial. Br J Surg. 2020;107(13):1791–800.
doi: 10.1002/bjs.11760
van der Wilk BJ, Noordman BJ, Neijenhuis LKA, et al. Active surveillance versus immediate surgery in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal cancer: a multicenter propensity matched study. Ann Surg. 2019 Oct 4. [Epub ahead of print]. Available at: https://journals.lww.com/annalsofsurgery/Abstract/9000/Active_Surveillance_Versus_Immediate_Surgery_in.94879.aspx